Strategic collaborations are accelerating the Personalized Gene Therapy Treatment Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Personalized Gene Therapy Treatment Market Over The Period 2026–2030?

The personalized gene therapy treatment market has experienced substantial growth in recent years. Its size is anticipated to increase from $8.38 billion in 2025 to $10.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.7%. This historical expansion can be linked to the rising occurrence of genetic disorders, progress in genomic sequencing technologies, early successful clinical trials of targeted gene therapies, the growth of specialized gene therapy research centers, and heightened investment in precision medicine.

The personalized gene therapy treatment market size is projected to experience rapid expansion in the coming years. This market is set to reach $21.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.4%. Factors driving this growth during the forecast period include a rise in regulatory approvals for personalized gene therapies, an escalating demand for tailored oncology treatments, the expansion of gene therapy manufacturing capacities, the growing incorporation of AI into therapy design, and the increasing uptake of pharmacogenomics-informed treatments. Key trends anticipated in the forecast period involve the wider adoption of gene editing-based therapies, a growing application of personalized treatment protocols, the increasing integration of companion diagnostics, the broader development of viral and non-viral vector platforms, and a heightened emphasis on precision oncology applications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28293&type=smp

Which Major Factors Are Driving The Expansion Of The Personalized Gene Therapy Treatment Market?

The rising occurrence of genetic disorders is anticipated to fuel the expansion of the personalized gene therapy treatment market in the future. These disorders stem from DNA irregularities that interfere with typical bodily functions, and their incidence is increasing partly due to advancing parental age, which correlates with a higher likelihood of mutations in older reproductive cells being passed to descendants. Personalized gene therapy offers a solution by precisely rectifying the faulty genes causing these conditions, customizing treatment to an individual’s unique genetic profile for better effectiveness and fewer side effects. For example, in October 2024, data from the Cystic Fibrosis Trust, a UK-based charity supporting cystic fibrosis patients, indicated that in 2022, approximately 11,148 individuals with cystic fibrosis (a genetic disorder) were registered, a figure that climbed to 11,318 in 2023, showing a 1.5% year-over-year increase in patient registrations. Consequently, the increasing prevalence of genetic disorders is a key factor propelling the growth of the personalized gene therapy treatment market.

How Is The Personalized Gene Therapy Treatment Market Divided Into Its Major Segments?

The personalized gene therapy treatment market covered in this report is segmented –

1) By Therapy: Targeted Treatments, Pharmacogenomics

2) By Vector Type: Viral, Non-Viral

3) By Distribution Channel: Hospitals, Clinics, Home Administration, Other Distribution Channels

4) By Application: Oncology, Neurology, Hematological, Infectious Diseases, Ophthalmology, Other Applications

Subsegments:

1) By Targeted Treatments: Monoclonal Antibodies, Chimeric Antigen Receptor T-Cell Therapy (CAR-T), Small Interfering RNA (siRNA) Therapy, Antisense Oligonucleotides (ASO), Gene Editing Therapy

2) By Pharmacogenomics: Companion Diagnostics, Drug Metabolism Enzyme Testing, Genetic Biomarker Analysis, Single Nucleotide Polymorphism (SNP) Profiling, Adverse Drug Reaction (ADR) Prediction

How Are Trends Transforming The Personalized Gene Therapy Treatment Market Landscape?

Leading companies within the personalized gene therapy treatment market are prioritizing the formation of strategic partnerships to enhance their technological capabilities and expedite the delivery of novel therapies to patients. These strategic partnerships represent cooperative agreements between entities, designed to harness their respective strengths and resources for collective advancement and a competitive edge, while also distributing both risks and rewards. An illustrative example occurred in May 2025, when Aldevron, a US-based firm specializing in DNA, RNA, and protein production, joined forces with Integrated DNA Technologies, a US-based provider of genomics solutions. Their collaboration resulted in the creation of the world’s inaugural mRNA-based personalized CRISPR therapy, intended to treat an infant suffering from urea cycle disorder (UCD), a rare and life-threatening genetic condition. This unique N of 1 therapy was conceived and brought to fruition in a mere six months, achieved through the development of a tailored guide RNA, an mRNA-encoded base editor, comprehensive off-target safety services, and a clinically validated lipid nanoparticle delivery mechanism. The creation of this therapy signifies a monumental achievement in the realm of personalized in vivo base-editing treatments.

Who Are The Prominent Organizations Shaping The Personalized Gene Therapy Treatment Market?

Major companies operating in the personalized gene therapy treatment market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation

Read the full personalized gene therapy treatment market report here:

https://www.thebusinessresearchcompany.com/report/personalized-gene-therapy-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Personalized Gene Therapy Treatment Market?

North America was the largest region in the personalized gene therapy treatment market in 2025. The regions covered in the personalized gene therapy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Personalized Gene Therapy Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28293&type=smp

Browse Through More Reports Similar to the Global Personalized Gene Therapy Treatment Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795